Notably, when we reclassified GC patients based on the combined expression levels of PDPN, CD31, and CCL2, those with high levels of all three proteins had significantly worse DFS (p < 0.0001; Figure 5G) and OS rates (p < 0.0001; Figure 5H) compared to those with low levels. This evidence concerns the gene CCL2 and gastric cancer.